| Document Date: 2011-04-13 07:09:59
Open Document File Size: 467,17 KBShare Result on Facebook
City Lexington / / Company Flagship Ventures / Flybridge Capital Partners / TARIS Biomedical / Third Rock Ventures / Polaris Venture Partners / PPD Inc. / / Country United States / / Currency USD / / Event Funding / Employment Change / / Facility Massachusetts General Hospital / Massachusetts Institute of Technology / / IndustryTerm venture capital / treatment of bladder diseases / treatment of multiple bladder disorders / therapeutics for genitourinary diseases / pharmaceutical / / MedicalCondition bladder diseases / overactive bladder / Bladder Disease Bladder diseases / bladder cancer / interstitial cystitis / chronic pelvic pain syndrome / diseases / bladder syndrome / urinary tract infections / genitourinary diseases / disorders / bladder disorders / severe interstitial cystitis / / MusicGroup Board of Directors / / Organization Board of Directors of TARIS Biomedical / Massachusetts General Hospital / Massachusetts Institute of Technology / / Person Kevin J. Bitterman / Ernest Mario / Sarma Duddu / Michael Cima / Michael J. Cima / Dennis A. Ausiello / Robert S. Langer / Cary Pfeffer / / Position President and CEO / board member / director / / Product Series B / Lidocaine / / ProvinceOrState Massachusetts / / Technology drug delivery / / URL www.tarisbiomedical.com / /
SocialTag |
TARIS CLOSES $18.3 MILLION SERIES B FINANCING -- Third Rock Ventures Leads Round -Lexington, MA – April 13 , 2011 – TARIS Biomedical®, a specialty pharmaceutical company pioneering the development of innovative, ta